Abstract
The availability of targeted molecules such as anti-apoptotic bcl-2 protein (BCL2i) or Bruton's tyrosine kinase (BTKi) inhibitors has revolutionized the treatment of chronic lymphocytic leukemia (CLL). Clinical studies have demonstrated the efficacy and safety of these molecules in the treatment of both newly diagnosed and relapsing/refractory disease.
A number of treatment regimens are available that are based on either continuous long-term BTKi monotherapy or fixed duration treatment combining venetoclax with another drug. Some of the advantages offered by the fixed duration therapy are discussed in the context of deciding on the appropriate therapy for a specific patient.